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Sphingosine kinase 2 and multiple myeloma
Nigel J. Pyne and Susan Pyne
News on: Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress 
by Wallington-Beddoe et al. Oncotarget. 2017; doi: 10.18632/oncotarget.17115
The survival of patients with Multiple Myeloma 
(MM) has improved due to the use of chemotherapeutic 
agents with autologous hematopoietic stem cell 
transplantation. However, the disease is incurable and 
relapse may occur within months. In addition, chemo-
resistance to agents, such as bortezomib can occur and 
therefore there is an unmet medical need. Sphingosine 
kinase 2 (SK2), the enzyme that catalyses formation of 
the bioactive lipid, sphingosine 1-phosphate (S1P) has 
UHFHQWO\EHHQLGHQWL¿HGDVDYLDEOHWDUJHWIRUWKHUDSHXWLF
intervention in MM [1]. Indeed, the SK2 inhibitor, 
ABC294640, has been shown to induce the down-
regulation of Mcl-1 and c-Myc leading to caspase-3-
dependent apoptosis of MM cells [1]. Moreover, SK2 
expression levels are increased in bone marrow CD138+ 
myeloma cells from patients [1]. 
Wallington-Beddoe et al. [2] in this issue of 
Oncotarget have analysed a larger gene expression data 
set from CD138+ bone marrow plasma cells from newly 
diagnosed myeloma patients compared to normal healthy 
controls. The authors found that there was increased 
expression of several genes involved in sphingolipid 
biosynthesis, including serine palmitoyltransferase, 
3-keto-dihydrosphingosine reductase, alkaline ceramidase 
and SK2. The expression levels of a second sphingosine 
NLQDVH LVRIRUP6.ZHUHQRWFKDQJHG7KHVH¿QGLQJV
suggest that SK2 is the predominant functional SK 
isoform in MM, and acts to remove ceramide to limit a 
ceramide burden and to promote MM cell survival via 
S1P-dependent mechanisms. The latter might include 
SK2/S1P-regulation of nuclear histone deacetylase-1/2 
(HDAC-1/2) [3] and telomerase reverse transcriptase 
(TERT) that sustains a replicative immortality programme 
in cancer cells [4]. Wallington-Beddoe et al. [2] have also 
PDGHDYHU\ VLJQL¿FDQW DGYDQFHE\GHPRQVWUDWLQJ WKDW
SK2 inhibitors induce a caspase-3-dependent apoptosis 
of MM cells via an endoplasmic reticulum stress (ER 
stress)/sustained unfolded protein response (UPR). 
Moreover, they provide evidence that non-lethal doses 
of SK2 inhibitors (e.g. K145) and bortezomib can lead 
to synergistic sustained UPR and CCAAT/enhancer 
binding protein (C/EBP) homologous protein (CHOP)-
LQGXFHGDSRSWRVLVRI00FHOOV7KHVH¿QGLQJVDUHYHU\
important because they provide mechanistic evidence for 
the action of SK2 inhibitors in cancer cells. Moreover, 
they suggest that combined treatment with SK2 inhibitors 
and bortezomib might allow use of lower doses of 
each, thereby avoiding/delaying chemo-resistance and 
LQFUHDVLQJWKHH൵HFWLYHQHVVRIWKHUDSHXWLFLQWHUYHQWLRQLQ
MM.
Bortezomib promotes the accumulation of 
protein which overwhelms the folding capacity of the 
ER to initiate ER stress and sustain UPR and which 
subsequently leads to apoptosis of CD138+ myeloma cells. 
This involves dissociation of the ER chaperone binding 
immunoglobulin protein (BiP) from the lumenal domains 
of ER stress sensors, which are protein kinase R-like 
(5NLQDVH3(5.LQRVLWROUHTXLULQJNLQDVH,5(Į
and activating transcription factor 6 (ATF6). Prolonged 
ER stress leads to sustained UPR activation that results 
in an increase in the expression of the pro-apoptotic 
transcription factor CHOP. Indeed, using a variety of 
MM cell lines, Wallington-Beddoe et al. [2] demonstrate 
that bortezomib induces sustained UPR as evidenced 
E\ LQFUHDVHG %L3 ;%3V SH,)Į DQG &+23 OHYHOV
In addition, they demonstrate that the SK2 inhibitor, 
K145, induces ER stress, which is shown by increased 
H[SUHVVLRQRI;%3VDQGSH,)Į+RZHYHU%L3LVRQO\
modestly increased in response to K145 and this provides 
the molecular basis for the synergism with bortezomib 
by allowing complementarity in the activation of ER 
stress sensors that result in CHOP-dependent apoptosis. 
This is also probably linked with the temporal activation 
NLQHWLFVRI,5(ĮDQG3(5.,QDGGLWLRQ.LQGXFHV
IRE1-dependent alarm activation of JNK and p38 
MAPK. The molecular basis of UPR activation by SK2 
inhibitors involves elevation of ceramide and changes in 
lipid composition of the ER membrane have been shown 
WRGLUHFWO\DFWLYDWH ,5(ĮDQG3(5. LQGHSHQGHQWO\RI
lumenal unfolded proteins [5]. Importantly, Wallington-
%HGGRHHWDO>@GHPRQVWUDWHWKDWWKH¿QGLQJVLQ00FHOO
lines are recapitulated in vivo using the 5TGM1 C57BL/
KaLwRij murine model of myeloma.
7KHVH ¿QGLQJV UDLVH D QXPEHU RI LPSRUWDQW
LVVXHV)LUVWPDQ\RIWKHH൵HFWVREVHUYHGZLWKWKH6.
inhibitor, K145, on ER stress/UPR and combination with 
bortezomib are recapitulated with the SK2 inhibitor, 
ABC294640 [2]. However, a previous study reported that 
ABC294640 directs c-Myc and Mcl-1 for proteasomal 
degradation and increases pro-apoptotic Noxa gene 
transcription to suppress growth of MM [1]. This might 
represent an early event in ER stress via deployment of 
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ER-associated degradation (ERAD) that is then switched 
to CHOP/caspase-3-induced apoptosis in the presence 
of bortezomib. Second, ABC294640 also inhibits 
dihydroceramide desaturase (Des1) [6, 7] that we have 
suggested might be a gate-keeper of the proteasome [6]. 
Third, we have also shown that the dual SK1/SK2 and 
Des1 inhibitor, SKi (4-([4-(4-chlorophenyl)thiazol-2-
yl] amino) phenol) induces an ER stress/UPR in T-cell 
lymphoblastic leukemic (T-ALL) cells that results in a 
protective cell survival autophagy [8]. Indeed, ER stress/
835YLD,5(Į-1.LVOLQNHGZLWK%HFOLQUHJXODWLRQ
that can orchestrate autophagic responses. In contrast, 
the SK2 selective inhibitor, (R)-FTY720 methylether 
failed to induce an ER stress/UPR response yet promoted 
autophagic death of T-ALL cells [8]. Clearly, the role of 
ER stress/UPR and regulation by SK2 has some cancer 
VSHFL¿FFRQWH[WEXWLWZRXOGEHLQWHUHVWLQJWRHYDOXDWHWKH
role of autophagy in the apoptotic process induced by SK2 
inhibitors in MM cells
Wallington-Beddoe et al. [2] place ER stress/
835DWWKHFHQWUHRIVSKLQJROLSLGDFWLRQDQGVSHFL¿FDOO\
ceramide/sphingosine/S1P regulation by SK2 in MM. 
3HUKDSV PRUH VLJQL¿FDQWO\ WKH\ KDYH GHPRQVWUDWHG
therapeutic potential for combined treatment using SK2 
LQKLELWRUVDQGERUWH]RPLE7KHVH¿QGLQJVSURYLGHLPSHWXV
for the development of nM potent SK2 inhibitors that can 
be translated to the clinic to treat myeloma.
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